Finance

Lists
Why is WAT up 2.17%?
Dive Deeper
WAT:NYSE
Waters Corp
$442.94
+2.17%
(+9.40) 1D
$442.94
0.00% (0.00)
After hours
Closed: Sep 28, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for WAT...
Open
$427.27
High
$445.48
Low
$423.89
Mkt. cap
43.52B
Avg. vol.
680.50K
Volume
981.50K
P/E ratio
110.76
52-wk high
$445.48
52-wk low
$282.77
EPS
$4.00
Beta
1.19
Shares outstanding
98.25M
No. of employees
8K
Open
$427.27
High
$445.48
Low
$423.89
Mkt. cap
43.52B
Avg. vol.
680.50K
Volume
981.50K
P/E ratio
110.76
52-wk high
$445.48
52-wk low
$282.77
EPS
$4.00
Beta
1.19
Shares outstanding
98.25M
No. of employees
8K
News stories
From web sources and news partners
Profile
Waters Corporation is an American company headquartered in Milford, Massachusetts that provides analytical instruments and software used for chromatography, mass spectrometry, laboratory informatics, and rheometry by the life sciences, materials, and food industries. The company has primary manufacturing facilities in 9 U.S. locations as well as 11 international locations including Wexford, Wilmslow, Birmingham, Hüllhorst, Singapore, Bangalore, Beijing, and Shanghai. Major brands include ACQUITY UPC² / UPLC Systems and columns, Xevo mass spectrometry systems, Synapt MS / HDMS systems, Zodiac HPLC columns, XTerra HPLC columns, XBridge columns, Alliance HPLC systems, Empower chromatography software, MassLynx mass spectrometry software, Oasis sample preparation products, and NuGenesis lab management system. Its primary competitors are Agilent Technologies, Thermo Fisher Scientific, Revvity, and Danaher. Wikipedia
About Waters Corp
CEOUdit Batra
Employees7.9K
Founded1958
HeadquartersMilford, Massachusetts, United States
SectorHealth care
Websitewaters.com
Analyst ratings
Based on 17 analysts giving stock ratings to WAT in the past 3 months
Buy
Buy
11
Hold
6
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for WAT in the last 3 months.
Highest
Current $442.94
$515.00 (+16.27%)
Average
$446.25 (+0.75%)
Lowest
$400.00 (-9.69%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eve Burstein
Bernstein
Buy
Maintained
$450.00
+1.6%
09/25/2026
Evie Koslosky
Goldman Sachs
Buy
Reiterated
$515.00
+16.3%
09/20/2026
Kallum Titchmarsh
Morgan Stanley
Hold
Maintained
$430.00
-2.9%
09/14/2026
Lu Li
UBS
Buy
Upgraded
$490.00
+10.6%
09/09/2026
Doug Schenkel
UBS
Buy
Upgraded
$490.00
+10.6%
09/09/2026
David Westenberg
Piper Sandler
Buy
Upgraded
$480.00
+8.4%
08/27/2026
Dan Leonard
RBC Capital
Buy
Maintained
$475.00
+7.2%
08/24/2026
Joanne Wuensch
Citi
Buy
Reiterated
$470.00
+6.1%
08/10/2026
Casey Woodring
J.P. Morgan
Hold
Maintained
$400.00
-9.7%
08/06/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$420.00
-5.2%
08/05/2026
Justin Bowers
Deutsche Bank
Hold
Reiterated
$400.00
-9.7%
08/05/2026
Subbu Nambi
Guggenheim
Buy
Reiterated
$440.00
-0.7%
08/04/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$440.00
-0.7%
08/04/2026
Daniel Arias
Stifel Nicolaus
Hold
Reiterated
$420.00
-5.2%
08/05/2026
Evan Stampler
Wells Fargo
Hold
Reiterated
$400.00
-9.7%
08/05/2026
Unknown Analyst
Wells Fargo
Hold
Reiterated
$400.00
-9.7%
08/05/2026
Daniel Brennan
TD Cowen
Buy
Upgraded
$475.00
+7.2%
08/07/2026
Luke Sergott
Barclays
Buy
Maintained
$460.00
+3.9%
08/05/2026
Matt Larew
William Blair
Buy
Maintained
-
-
08/04/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
$415.00
-6.3%
08/04/2026
Sidharth Sahoo
HSBC
Buy
Maintained
$435.00
-1.8%
06/03/2026
Michael Polark
Wolfe Research
Buy
Maintained
$425.00
-4.1%
06/01/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
$370.00
-16.5%
05/14/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$387.00
-12.6%
05/06/2026
Patrick B Donnelly
Citi
Buy
Reiterated
$425.00
-4.1%
04/07/2026
Tycho Peterson
Jefferies
Buy
Reiterated
$470.00
+6.1%
02/10/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$3.05 / $3.01
+1.41%beat
Revenue / Est. (USD)
1.64B / 1.62B
+1.38%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Apr 2026
Jul 2026
Revenue
799.89M
932.36M
1.27B
1.64B
Cost of goods sold
327.81M
362.86M
679.00M
757.00M
Cost of revenue
327.81M
362.86M
679.00M
757.00M
Research and development expenses
53.64M
46.90M
95.00M
121.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
187.23M
195.78M
305.00M
368.00M
Operating expense
252.97M
254.76M
552.00M
733.00M
Total operating expenses
580.77M
617.62M
1.23B
1.49B
Operating income
219.11M
314.74M
36.00M
155.00M
Other non operating income
-69.00K
2.06M
1.00M
-
EBT including unusual items
170.12M
264.18M
-88.00M
-141.00M
EBT excluding unusual items
197.12M
308.18M
-5.00M
100.00M
Income tax expense
21.20M
38.97M
-16.00M
-5.00M
Effective tax rate
12.46%
14.75%
18.18%
3.55%
Other operating expenses
-
-
-
-
Net income
148.92M
225.21M
-72.00M
-136.00M
Net profit margin
18.62%
24.16%
-5.68%
-8.27%
Earnings per share
3.40
4.53
2.70
3.05
Interest and investment income
4.71M
5.67M
6.00M
5.00M
Interest expense
-26.64M
-14.29M
-48.00M
-60.00M
Net interest expenses
-21.92M
-8.62M
-42.00M
-55.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
271.79M
367.28M
243.00M
456.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps